MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$14,967,491
EPS
-$0.15
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
12,529,567
7,015,299
5,571,839*
8,722,104
General and administrative
2,437,924
2,328,500
2,181,251*
1,888,376
Loss from operations
-14,967,491
-9,343,799
-7,753,090*
-10,610,480
Interest income
-
-
667,229*
-
Other income (expense)
-
-
119,231*
-
Net loss
-
-
-6,966,630
-
Basic EPS
-0.15
-0.09
-0.073
-0.1
Diluted EPS
-0.15
-0.09
-0.073
-0.1
Basic Average Shares
95,183,718
95,183,718
95,186,179
95,185,187
Diluted Average Shares
95,183,718
95,183,718
95,186,179
95,185,187
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Loss from operations
-$14,967,491
(-53.38%↓ Y/Y)
Research and development
$12,529,567
General and
administrative
$2,437,924
Buy us a coffee
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)